Clinical Trial Update: Atrial Fibrillation Feasibility Certoparin Trial - AFFECT [Phase 3]

View source ↗

Summary

Phase 3 feasibility trial of Certoparin for persistent nonvalvular atrial fibrillation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Persistent Nonvalvular Atrial Fibrillation

Drugs mentioned

• Certoparin (certoparin)

Snippet

Sponsor: Novartis | Conditions: Persistent Nonvalvular Atrial Fibrillation | Phase 3 | Status: COMPLETED